A multicenter comparison between autologous saphenous vein and heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft in the treatment of critical limb ischemia in diabetics  by Dorigo, Walter et al.
A multicenter comparison between autologous
saphenous vein and heparin-bonded expanded
polytetrafluoroethylene (ePTFE) graft in the
treatment of critical limb ischemia in diabetics
Walter Dorigo, MD,a Raffaele Pulli, MD,a Patrizio Castelli, MD,b Vittorio Dorrucci, MD,c
Fiore Ferilli, MD,d Giovanni De Blasis, MD,e Vincenzo Monaca, MD,f Enrico Vecchiati, MD,g and
Carlo Pratesi, MDa on behalf of the Propaten Italian Registry Group, Florence, Varese, Venice-Mestre,
Terni, Avezzano, Catania, and Reggio Emilia, Italy
Objectives:The aimof this studywas to evaluate early and follow-up results of below-knee bypasses performedusing a bioactive
heparin-treated expanded polytetrafluoroethylene (ePTFE) graft in diabetic patients with critical limb ischemia (CLI) in a
multicenter retrospective registry involving seven Italian vascular centers and to compare themwith those obtained in patients
operated on with autologous saphenous vein (ASV) in the same centers in the same period of time.
Methods: Over an 8-year period, ending in 2009, a heparin-bonded prosthetic graft (Propaten Gore-Tex; W. L. Gore &
Associates Inc, Flagstaff, Ariz) was implanted in 180 diabetic patients undergoing below-knee revascularization for CLI in
seven Italian hospitals (group 1). In the same period in these seven centers, 133 below-knee bypasses with ipsilateral ASV in
diabetics with CLI were performed (group 2). Data concerning these interventions were retrospectively collected in a
multicenter registry with a dedicated database. Early (<30 days) results were analyzed in terms of graft patency, major
amputation rates, and mortality. Follow-up results were analyzed in terms of primary and secondary graft patency, limb
salvage, and survival.
Results:The interventions consisted of below-knee bypasses in 132 cases in group 1 (73%) and in 45 cases in group 2 (33%;P<
.001); 48 patients in group 1 (27%) and 88 patients in group 2 (67%;P< .001) had distal tibial anastomosis. Patients in group
1 had more frequently adjunctive procedures performed at distal anastomotic sites to improve run-off status. Postoperative
and long-termmedical treatment consisted of single antiplatelet therapy in 93 cases (52%) in group 1 and in 64 cases (48%,P
ns) in group 2, of double antiplatelet therapy in 18 cases (10%) in group 1 and in four cases (3%; P .05) in group 2 and of
oral anticoagulants in 69 patients in group 1 (38%) and in 65 (49%; P  .02) in group 2. Mean duration of follow-up was
28.3  21.4 months; 308 patients (98%) had at least one postoperative clinical and ultrasonographic examination and 228
(72%) reached at least a 1-year follow-up. Estimated 48-month survival rates were 76.6% in group 1 and 72.7% in group 2
(P  > .9, log-rank 0.08). Primary patency rate at 48 months was significantly better in group 2 (63.5%) than in group 1
(46.3%; P  .03, log-rank 4.1). Assisted primary patency rates at 48 months were 47.3% (SE 0.05) in group 1 and 69% (SE
0.05) in group 2 (P  .01, log-rank 6.3). The rates of secondary patency at 48 months were 57.5% in group 1 and 69.6% in
group 2 (P  .1, log-rank 2.3); the corresponding values in terms of limb salvage and amputation free-survival rates were
75.4% and 82.4% (P  .3, log-rank 1), and 59.9% and 64.4% (P  .3, log-rank 0.9), respectively.
Conclusions:Data from this large, retrospective registry confirmed that the indexed heparin-bonded ePTFE graft provides
satisfactory early and midterm results in diabetic patients undergoing surgical treatment of CLI. While autologous
saphenous vein maintains its superiority in terms of primary patency, secondary patency rates are not statistically
different, even in the presence of a trend for improved secondary patency with vein graft; and also limb salvage rates are
comparable. ( J Vasc Surg 2011;54:1332-8.)
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1332Diabetes mellitus has been reported to significantly affect
ong-term patency and limb salvage rates in surgical lower limb
evascularizations in patients with peripheral arterial disease.1,2
ultiple studies and an international consensus3 have concluded
hat autologous vein conduit offers better long-term patency
hanprosthetic grafts in below-knee revascularizations in patients
ith critical limb ischemia (CLI), and this was also in diabetics.4
n recent years, the use of heparin-bonded grafts has been pro-
osed as an alternative to autologous vein to reduce both early
hrombotic risk and late myointimal hyperplasia development,
ndwe reported satisfactory early andmidterm results in patients
ndergoing surgical treatment of CLI using a bioactive polytet-
afluoroethylene (PTFE) graft with a covalent end point attach-
ent of heparin.5
The aim of this study was to evaluate early and
ollow-up results of below-knee bypasses performed with
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Volume 54, Number 5 Dorigo et al 1333this bioactive heparin-treated expanded polytetrafluoro-
ethylene (ePTFE) graft in diabetic patients with CLI in a
multicenter retrospective registry involving seven Italian
vascular centers and to compare them with those obtained
in patients operated on with autologous saphenous vein
(ASV) in the same centers in the same period of time.
METHODS
Over an 8-year period, ending in 2009, a heparin-
bonded prosthetic graft (Propaten Gore-Tex; W. L. Gore
& Associates Inc, Flagstaff, Ariz) was implanted in 503
patients undergoing below-knee revascularization for CLI
in seven Italian hospitals. Data concerning these interven-
tions were collected in a multicenter registry with a dedi-
cated database. The modalities of the choice of the type of
graft and of data collection and insertion have been already
described.5 The choice to use a prosthetic graft was made
on the basis of surgeons’ discretion and not only in the
absence of a suitable vein.
The reliability of the data contained in the registry was
certified by an external validation (Castalia Group, ICT and
Quality Management, Aosta, Italy).
A retrospective analysis of the database was performed
and 180 diabetics were found (group 1). In the same period
in the same seven centers, 133 diabetic patients with CLI
had a below-knee bypass with ipsilateral ASV (group 2). In
these patients, the diameter of the vein was at least 3 mm on
duplex ultrasonography scan, and this finding was con-
firmed at operation.
The presence of diabetes mellitus was defined as the
need for specific drugs. Early (30 days) results were
analyzed in terms of graft patency, major amputation rates,
and mortality. Graft patency was defined as the possibility
to maintain a functioning graft without adjunctive inter-
ventions. Major amputation was defined as the occurrence
of amputation at above-knee or below-knee level. The
results in the two groups were compared with 2 test and
Fisher exact test, when necessary.
Follow-up was performed within the third postopera-
tive month, at 12 months, and then yearly, and consisted of
clinical examination, ankle-brachial index (ABI) measure-
ments, and graft duplex examination. Graft failure was
diagnosed when ABI deterioration was associated with
duplex evidence of graft thrombosis. Angiography and
reintervention were indicated when recurrence of CLI or
acute limb ischemia occurred.
Follow-up results were analyzed in terms of primary
(the possibility to maintain a functioning graft without
adjunctive interventions), assisted-primary (the possibility
to maintain a functioning graft with adjunctive interven-
tions), and secondary (the possibility to restore graft pa-
tency when a thrombosis occurred) graft patency, limb
salvage (the absence of amputation at above-knee or below-
knee level), and survival with Kaplan-Meier curves. The
results in the two groups were compared by means of
log-rank test. Univariate and multivariate analysis (Cox’s
regression) of the factors affecting primary and secondary
patency in the whole group were performed. In Cox regres- aion analysis, the factors with statistical significance at uni-
ariate analysis were included. Pre- and postoperative ABI
alues were compared with the t test for independent
amples. Statistical significance was defined as a P value less
han .05.
ESULTS
Demographic data, clinical and anatomical status.
here were no differences between the two groups in terms
f median age; there was a higher frequency of female
atients in group 2, whereas patients in group 1 had, more
requently, a history of smoking, hyperlipemia, and coro-
ary artery disease than patients in group 2. Demographic
ata, comorbidities, and main risk factors for atherosclero-
is in the two groups are summarized in Table I.
Indication for surgical intervention was the presence of
LI in all patients; 115 patients in group 1 (64%) and 73 in
roup 2 (55%; P  .1) had Rutherford’s class6 5 and 6
linical status. Secondary interventions, defined as a rein-
ervention for the late occlusion of a prior open or endo-
ascular femoropopliteal revascularization, accounted for
0 cases in group 1 (33%) and for 18 cases in group 2
13.5%, P  .001).
Patients in group 2 had, more frequently, only one
atent tibial vessel than patients in group 1 (67% and 47%,
espectively; P  .001).
Mean preoperative ABI in the affected limb was 0.22
standard deviation [SD] 0.20), without differences be-
ween the two groups (0.31 in group 1 and 0.25 in group
, P  .09).
Surgical interventions and drug therapy. Intervention
onsisted of a below-knee bypass in all the cases. Surgical
echnical details in the two groups are reported in Table II;
atients in group 2 had a higher percentage of distal tibial
nastomosis than patients in group 1 (67% and 27%, respec-
ively, P  .001), whereas patients in group 1 had more
requently, adjunctive procedures performed at distal anas-
omotic sites to improve run-off status. In group 2, in situ
ein bypass was used in 63 patients, whereas the remaining
ad an inverted vein bypass.
Postoperative and long-term medical treatment con-
isted of single antiplatelet therapy in 93 cases (52%) in
roup 1 and in 64 cases (48%, P ns) in group 2, of double
able I. Demographic data, comorbidities, and main risk
actors for atherosclerosis in the two groups
Group 1
(180 int.)
Group 2
(133 int.) P
emale sex 39 (22%) 51 (39%) .001
edian age (years) 72.5 72.9 .6
istory of smoking 137 (76%) 70 (52.5%) .001
yperlipemia 114 (63%) 69 (52%) .04
rterial hypertension 163 (90%) 112 (84%) .09
oronary artery disease 99 (55%) 51 (38%) .004
hronic renal failure 32 (18%) 20 (15%) .5ntiplatelet therapy in 18 cases (10%) in group 1 and in four
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November 20111334 Dorigo et alcases (3%; P .05) in group 2, and of oral anticoagulants in
69 patients in group 1 (38%) and in 65 (49%; P  .02) in
group 2, the regimen for anticoagulation or antiplatelet
being determined just on the basis of the surgeon’s prefer-
ence.
Early results. There were four perioperative deaths,
all in group 1 (mortality rate 2.2%; P  .08 with respect to
group 2). The cause of death was acute myocardial infarc-
tion in three cases and pulmonary embolism in the remain-
ing one.
One case of perioperative severe bleeding (requiring
surgical revision at the distal anastomosis) occurred in a
patient in group 1. No case of postoperative heparin-
induced thrombocytopenia was recorded in both groups.
Mean postoperative hospital stay was 13.3 days in group 1
and 16.2 days in group 2 (P  .8; 95% CI -10.7/4.9).
Early graft thrombosis occurred in 23 patients (14 in
group 1 and nine in group 2), with cumulative 30-day graft
patency rates of 92.2% and 93.2%, respectively (P  .7).
There were 13 early major amputations (nine in group 1
and four in group 2), with 30-day major amputation rates
of 5% and 4%, respectively (P  .3).
Follow-up results. Mean duration of follow-up was
28.3  21.4 months; 308 patients (98%) had at least one
postoperative clinical and ultrasonographic examination
and 228 (72%) reached at least a 1-year follow-up.
Mean ABI value during follow-up was 0.59 (compared
with 0.22 preoperatively; P  .001), with a significant
increase in both groups.
During follow-up, 43 deaths (23 in group 1 and 20 in
group 2), 85 new graft thomboses (58 in group 1 and 27 in
group 2), and 41 major amputations (25 in group 1 and 16
in group 2) occurred. In seven cases (one in group 1 and six
Table II. Surgical technical details in the two groups
Group 1
(180 int.)
Group 2
(133 int.) P
Inflow vessels
● External iliac 4 (2%) 2 (1.5%) n.s.
● Common femoral 172 (95%) 116 (87%) n.s.
● Superficial femoral 4 (3%) 15 (11.5%) .004
Distal tibial
anastomosis
48 (27%) 88 (66%) .001
Outflow vessels
● BK popliteal artery 132 (73%) 45 (33%) .001
● Tibioperoneal
trunk
23 (12.5%) 11 (8%) .06
● Peroneal artery 5 (2.5%) 15 (11%) .004
● Anterior tibial
artery
10 (6%) 33 (25%) .001
● Posterior tibial
artery
10 (6%) 29 (23%) .001
Adjunctive distal
procedures
42 (23%) 12 (9%) .001
● Vein cuff 34 4
● Patching 8 7
● Tibial PTA – 1
BK, Below knee; PTA, percutaneous transluminal angioplasty.in group 2), significant stenoses at anastomotic sites with- uut graft thrombosis were detected; in five cases, percuta-
eous transluminal angioplasty of the distal anastomosis
as performed; while in the remaining patients, endarter-
ctomy of the common femoral artery with patching of the
roximal anastomosis was required.
Estimated 48-month survival rates were 76.6% in group
(standard error [SE] 0.05) and 72.7% in group 2 (SE
.06; P  .9, log-rank 0.08). Primary patency rate at 48
onths was significantly better in group 2 (63.5%, SE 0.05)
han in group 1 (46.3%, SE 0.05; P .03, log-rank 4.1; Fig
). In below-knee bypasses, the corresponding figures were
6.5% in group 1 (SE 0.06) and 76% in group 2 (SE 0.07;
 .02, log-rank 5.1); in tibial bypasses, they were 45.8%
SE 0.1) and 58% (SE 0.06; P  .4, log-rank 0.6).
Assisted primary patency rates at 48 months were
7.3% (SE 0.05) in group 1 and 69% (SE 0.05) in group 2
P  .01, log-rank 6.3).
In group 1, among patients with graft thrombosis, 15
nderwent successful reintervention, 24 underwent major
mputation despite the attempts of further revasculariza-
ion, whereas in the remaining 24 patients, graft thrombo-
is caused intermittent claudication without critical or acute
imb ischemia and nonoperative management was decided;
nd one patient had below-knee amputation despite the
resence of patent bypass for severe foot infection. In group
, only four out of the 27 patients presenting with vein
hrombosis had successful reintervention; 16 patients un-
erwent major amputation despite the attempts of further
evascularization, and seven patients with vein thrombosis
ithout critical ischemia underwent nonoperative manage-
ent. All the patients with graft thrombosis undergoing
onoperative management for the absence of critical or
cute ischemia had their limb salvaged. The rates of second-
ry patency at 48 months were 57.5% in group 1 (SE 0.05)
nd 69.6% in group 2 (SE 0.05), without significant differ-
nces between the two groups (P .1, log-rank 2.3; Fig 2);
he corresponding values in terms of limb salvage and
mputation free-survival rates were 75.4% (SE 0.04) and
2.4% (SE 0.04; P  .3, log-rank 1), and 59.9% (SE 0.05)
nd 64.4% (SE 0.05; P  .3, log-rank 0.9), respectively.
At univariate analysis, secondary intervention, poor
un-off score and type of graft were found to significantly
ffect long-term primary patency and this was also at mul-
ivariate analysis (Table III); as far as secondary patency is
oncerned, secondary intervention, the presence of ulcers
nd a poor round-off score were found to significantly
ffect it at univariate analysis, while at multivariate analysis,
nly the presence of ulcers and of a poor run-off status
aintained their significance (Table IV).
ISCUSSION
The ideal material for below-knee revascularizations
s an autogenous vein conduit that has been demon-
trated to provide significantly better results than pros-
hetic grafts.4 However, the availability of such a conduit
s a relevant limitation of lower extremity bypass surgery:
ood ipsilateral greater saphenous vein may be lacking in
p to 40% of the patients,7 and the strong relationship
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Volume 54, Number 5 Dorigo et al 1335between vein diameter and graft failure makes autolo-
gous saphenous vein unsuitable in some 25% of the
patients with CLI.8
In these situations, the use of a prosthetic graft may be
unavoidable: the most common used synthetic material is
ePTFE, which has provided results similar to those
achieved with autologous vein in above-knee revasculariza-
tions in the first 24 postoperative months,9 but poorer
results in below-knee interventions.10
In the last years, several attempts have been made to
develop prosthetic materials with intrinsic thrombosis
resistance given by modifications of chemical and physical
graft properties. In particular, the use of heparin bonded to
biomaterial surfaces has been suggested.11,12 Researchers
have proposed the immobilization of the heparin on the
graft with covalent end point linkages to maintain a pro-
Fig 1. Kaplan-Meier curves for primary patency rates d
error (SE) values.longed bioactivity on the antithrombin sites of the bound teparin,13 and several studies reported promising results
ith this graft.14-16
We reported satisfactory results also in our multicenter
egistry5 at an intermediate follow-up period, with a pri-
ary patency rate of 61% and a limb salvage of 83% after 3
ears in patients with CLI undergoing below-knee revascu-
arizations. In this study, diabetics accounted for more than
0% of the patients and no influence of diabetes on early
nd follow-up results was found.
Whereas the presence of diabetes mellitus in patients
ndergoing lower limb revascularization has been re-
orted by some authors2 to significantly impair graft
atency rates, other studies have demonstrated that dia-
etes is not a risk factor for vein graft failure.1,8,17 On the
ther hand, there is general consensus regarding the role
f diabetes in reducing limb salvage and long-term pa-
follow-up with number of patients at risk and standarduringient survival in comparison to people without diabetes.
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November 20111336 Dorigo et alIn the present study, we have compared the results
obtained in diabetic patients using the indexed ePTFE
grafts with those obtained using autologous saphenous
vein in the seven centers participating to the registry in the
same time interval.
The modality of enrollment of our patients could be
criticized, as no randomization was planned and, as a
consequence, the two groups differed in several aspects.
While there were no differences between the two groups in
terms of clinical presentation and Rutherford’s classifica-
tion, run-off status was found to be significantly poorer in
patients undergoing saphenous vein bypass, and in these
cases, a tibial distal anastomosis became more frequent. On
the other hand, among patients treated with the modified
ePTFE graft, the percentage of reinterventions was signif-
Fig 2. Kaplan-Meier curves for secondary patency rates
error (SE) values.icantly higher, and an adjunctive distal procedure to im- drove the run-off was more frequent, too. These differences
robably reflect different approaches and different patient
election among the participating surgeons: because of its
ature, the registry does not have either inclusion and
xclusion criteria or homogenous indication for the choice
f the grafts. This selection bias represents the main limita-
ion of this study, affecting its the design, the comparison of
he two groups, and the interpretation of the results. On
he other hand, in our opinion, this study could provide a
eliable cross-section of the everyday practice in Italian
ascular centers.
Our results confirmed earlier results in terms of excellent
afety, with a negligible rate of perioperative bleeding requir-
ng surgical revision, graft patency, and amputation rates.
There was a trend toward a higher rate of perioperative
g follow-up with number of patients at risk and standarddurineaths in group 1, which is probably related to the higher
t
t
r
c
p
b
i
p
p
c
t
i
b
c
t
r
w
s
g
l
p
o
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 5 Dorigo et al 1337percentage of coronary artery disease among these patients,
acute myocardial infarction being the most common cause
of perioperative death in our series.
Median duration of follow-up in our registry was more
than 28 months, which is similar to the recent study from
Daenens et al16 who reported, in a 2-year monocenter
retrospective study, similar results between autologous sa-
phenous vein and heparin-bonded ePTFE in terms of pri-
mary patency and limb salvage, however, without an anal-
ysis of subgroups, such as diabetics.
Differently from the above-cited report, we found sig-
nificantly poorer primary patency rates after 4 years among
patients treated with the PTFE graft, despite the more
frequent use of adjunctive procedures in these cases; even if
secondary patency rates did not differ under a strict statis-
tical standpoint, there was a trend for improved secondary
patency with vein grafts (possible type 1 statistical error).
However, an 11% increase in secondary patency rates in
group 1 compared with primary patency seems to suggest
the possibility of effectively treating occluded heparin-
bonded grafts. On the other hand, the low rate of successful
reinterventions in patients with occluded vein bypass seems
to confirm what most surgeons can observe in their every-
day practice, that it is really difficult to restore vein patency
Table III. Univariate and multivariate (for significant fa
follow-up
Univariate an
Log-rank P
Female gender 0.6 .4
Chronic renal failure 0.04 .9
Reintervention 10.6 .001
Tibial anastomosis 0.03 .9
Rutherford class 5-6 3.4 .06
Distal procedures 1.9 .1
Run-off score 0-1 5.1 .02
Antiplatelet treatment 0.6 .4
ePTFE graft 4.1 .03
ePTFE, Expanded polytetrafluoroethylene.
Table IV. Univariate and multivariate (for significant fa
follow-up
Univariate an
Log-rank P
Female gender 0.02 .8
Chronic renal failure 0.01 .9
Reintervention 4.3 .03
Tibial anastomosis 1 .3
Rutherford class 5-6 4 .04
Distal procedures 1.2 .2
Run-off score 0-1 5.9 .01
Antiplatelet treatment 1.2 .1
ePTFE graft 2.4 .1
ePTFE, Expanded polytetrafluoroethylene.once occlusion has occurred. As a consequence, the detec- tion of flow-limiting vein stenoses during follow-up and
heir prompt treatment prior to vein thrombosis frequently
esult in improved patency and, also, in our experience,
onfirming the need for a prolonged surveillance of these
atients. The rate of 4-year amputations was not different
etween autologous vein and heparin-bonded ePTFE. This
s an encouraging result, considering that limb salvage
robably represents the main outcome in all these critical
atients.
The analysis of the factors affecting follow-up out-
omes demonstrated that, beyond the graft material, pa-
ients with poor run-off status and undergoing secondary
nterventions were more likely to lose primary patency at
oth univariate and multivariate analysis. These findings
ould support continuous use of autologous materials in
hese subgroups of patients; on the contrary, the good
esults after 4 years in primary interventions and in patients
ith more than one patent distal vessel, could suggest a
ignificant role of this heparin-bonded graft in such sub-
roups.
As previously introduced, the present study has several
imitations. Moreover, estimates of graft patency and am-
utation rates could have been biased by the competing risk
f death for these other two outcomes, potentially reducing
at univariate) analysis for primary patency during
s Multivariate analysis
% CI OR 95% CI OR P
-1.1 0.6
-1.6 0.9
-0.7 0.5 0.4-1 0.6 .05
-1.4 0.9
-2.1 1.4
-2.1 1.3
-2.2 1.5 1-2.3 1.5 .03
-1.6 1.1
-2.4 1.6 0.9-2-2 1.4 .05
at univariate) analysis for secondary patency during
s Multivariate analysis
CI OR 95% CI OR P
-1.6 1
-1.7 0.9
-0.9 0.6 0.4-1.1 0.6 .06
-1.8 1.2
-2.4 1.5 0.9-2.4 1.5 .05
-2.2 1.3
-2.7 1.6 0.9-2.3 1.5 .05
-1.9 1.2
-2.1 1.4ctors
alysi
95
0.4
0.6
0.3
0.6
0.9
0.8
1
0.8
1ctors
alysi
95%
0.6
0.5
0.4
0.8
1
0.8
1.1
0.8
0.9he value of our results. Despite these limits and bias, our
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November 20111338 Dorigo et alresults demonstrated that the heparin-bonded ePTFE graft
can represent a safe alternative to autologous saphenous
vein, mainly when it is unsuitable or of poor quality.
CONCLUSIONS
Data from this large, retrospective registry confirmed
that the indexed heparin-bonded ePTFE graft provides
satisfactory early and midterm results in diabetic patients
undergoing surgical treatment of CLI. While autologous
saphenous vein maintains its superiority in terms of primary
patency, secondary patency and limb salvage rates are not
statistically different even in the presence of a trend for
improved secondary patency with vein graft.
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